ArticleJournal of inflammation research2026
Cell Death Index Predicts Sepsis Outcomes and Highlights Necroptosis as a Therapeutic Target.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Excessive immunogenic cell death (ICD) drives early mortality in sepsis, but its dominant subtype and clinical relevance remain poorly defined. Methods: We systematically screened 3,421 genes involved in 15 forms of cell death across multiple sepsis transcriptomic datasets. Machine learning and COX regression identified two ICD-associated genes (PDZD8 and ADRB2) and were used to build a Cell Death Index (CDI). CDI performance was verified in terms of discrimination, risk stratification and clinical relevance. Gene set scoring was used to assess the association of CDI with necroptosis. Single-cell RNA sequencing was performed to investigate PDZD8 and ADRB2 expression and function. Treatment with the necroptosis inhibitor Necrostatin-1 (Nec-1) was evaluated in a cecal ligation and puncture (CLP) mouse model. Results: The CDI robustly predicted sepsis prognosis across multiple datasets (AUC: 0.628-0.70). Multivariate analysis identified CDI as an independent risk factor for 28-day mortality (OR = 1.63-2.91, p < 0.001). CDI levels were significantly elevated in sepsis patients compared to pneumonia and upper respiratory infection patients. Meanwhile, serum high-mobility group box 1 (HMGB1) was markedly elevated in sepsis cases, whereas caspase-8 (CASP8) remained unchanged, supporting an active necroptotic process. Single-cell RNA sequencing revealed that PDZD8 was highly expressed in neutrophils and associated with oxidative stress and necroptosis, while ADRB2 was enriched in NK cells and linked to suppressed inflammatory signaling. Treatment with Nec-1 in the CLP model significantly improved survival (from 0% to 90%), reduced inflammatory cytokine release, and alleviated organ damage. Conclusion: This study identifies necroptosis as the dominant ICD subtype driving immune imbalance in sepsis and establishes CDI as a clinically relevant prognostic biomarker, thereby providing mechanistic insight into sepsis pathogenesis and lay the groundwork for precision therapeutic interventions targeting necroptosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.